David Sass

Appearances

CLINICAL RESPONSES TO TERLIPRESSIN IN THE SUBGROUP OF PATIENTS WITH HEPATORENAL SYNDROME FURTHER COMPOUNDED BY ALCOHOLIC HEPATITIS: ANALYSIS OF THE CONFIRM PHASE III STUDY
Date
May 8, 2023
BACKGROUND: Hepatorenal syndrome (HRS) with rapidly deteriorating kidney function can be effectively reversed when treated with terlipressin, the US FDA-approved vasopressin analogue…
Presenter
Kevin Korenblat
Speakers
Juan Gallegos-Orozco
David Sass
Kalyan Bhamidimarri
Rohit Satoskar
Charles Landis
Zunaira Zafar
Mohammad Khan
Khurram Jamil